Thomas J. Riga net worth and biography

Thomas Riga Biography and Net Worth

Thomas Riga has served as our Chief Operating Officer since December 2017, as Executive Vice President, Chief Operating Officer & Head of Business Development since May 2017 and as our Senior Vice President & Chief Commercial Officer since August 2014. From July 2013 to August 2014, he served as our Vice President, Corporate Accounts. During his tenure as Chief Operating Officer, Mr. Riga has led Spectrum’s focus from a specialty pharmaceutical company to a development-focused organization. The divestiture of seven marketed products infused non-dilutive capital back into the organization and enabled Spectrum to further advance its two cornerstone, value driving assets. As Chief Commercial Officer, he led multiple product launches in the oncology market, delivering innovative cancer care while establishing world class partnerships with key industry stakeholders. He has consistently inspired cross-functional teams to deliver superior performance to create value for Spectrum and optimized the commercial organization to advance our competitive advantage.

Mr. Riga has over 20 years of pharmaceutical leadership experience. He has management experience in various positions at Wyeth Ayerst Pharmaceuticals, Eli Lilly and Company, Amgen Inc. and Dendreon Pharmaceuticals LLC. Throughout his career he has successfully integrated leadership and strategy to create meaningful value. His executive leadership experience spans across operations, business development, sales, marketing, Six Sigma (black belt), manufacturing, and corporate accounts. Mr. Riga is an accredited public company director from UCLA’s Anderson School of Business.

Mr. Riga holds a bachelor’s degree in Biology and Chemistry from St. Lawrence University, Canton, New York.

What is Thomas J. Riga's net worth?

The estimated net worth of Thomas J. Riga is at least $408,726.45 as of March 14th, 2023. Mr. Riga owns 503,792 shares of Spectrum Pharmaceuticals stock worth more than $408,726 as of March 21st. This net worth estimate does not reflect any other assets that Mr. Riga may own. Learn More about Thomas J. Riga's net worth.

What is Thomas J. Riga's salary?

As the COO of Spectrum Pharmaceuticals, Inc., Mr. Riga earned a total compensation package of $2,788,857.00 in 2021. Mr. Riga earned a salary of $550,000.00, a bonus of $364,000.00, stock awards of $478,500.00, options awards of $1,290,829.00, and other compensation of $105,528.00. Learn More on Thomas J. Riga's salary.

How do I contact Thomas J. Riga?

The corporate mailing address for Mr. Riga and other Spectrum Pharmaceuticals executives is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. Spectrum Pharmaceuticals can also be reached via phone at (702) 835-6300 and via email at [email protected] Learn More on Thomas J. Riga's contact information.

Has Thomas J. Riga been buying or selling shares of Spectrum Pharmaceuticals?

During the past quarter, Thomas J. Riga has sold $89,945.47 of Spectrum Pharmaceuticals stock. Most recently, Thomas J. Riga sold 18,153 shares of the business's stock in a transaction on Tuesday, March 14th. The shares were sold at an average price of $0.82, for a transaction totalling $14,885.46. Following the completion of the sale, the chief executive officer now directly owns 503,792 shares of the company's stock, valued at $413,109.44. Learn More on Thomas J. Riga's trading history.

Who are Spectrum Pharmaceuticals' active insiders?

Spectrum Pharmaceuticals' insider roster includes Seth Fischer (Director), Francois Lebel (Insider), Keith Mcgahan (Insider), and Thomas Riga (COO). Learn More on Spectrum Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Spectrum Pharmaceuticals?

During the last twelve months, Spectrum Pharmaceuticals insiders bought shares 1 times. They purchased a total of 50,000 shares worth more than $22,500.00. During the last twelve months, insiders at the biotechnology company sold shares 11 times. They sold a total of 218,922 shares worth more than $139,969.16. The most recent insider tranaction occured on March, 14th when insider Keith M Mcgahan sold 15,733 shares worth more than $12,901.06. Insiders at Spectrum Pharmaceuticals own 2.7% of the company. Learn More about insider trades at Spectrum Pharmaceuticals.

Information on this page was last updated on 3/14/2023.

Thomas J. Riga Insider Trading History at Spectrum Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/14/2023Sell18,153$0.82$14,885.46503,792View SEC Filing Icon  
2/22/2023Sell37,009$0.77$28,496.931,839,639View SEC Filing Icon  
1/30/2023Sell69,389$0.54$37,470.062,008,022View SEC Filing Icon  
1/3/2023Sell23,929$0.38$9,093.021,189,411View SEC Filing Icon  
3/15/2022Sell20,356$0.70$14,249.20View SEC Filing Icon  
2/23/2022Sell19,953$0.70$13,967.10View SEC Filing Icon  
5/13/2021Sell3,402$3.09$10,512.18409,129View SEC Filing Icon  
3/15/2021Sell23,291$3.62$84,313.42431,359View SEC Filing Icon  
1/19/2021Sell76,283$3.97$302,843.51351,915View SEC Filing Icon  
5/13/2020Sell2,086$3.25$6,779.50417,558View SEC Filing Icon  
3/31/2020Sell1,854$2.31$4,282.74420,582View SEC Filing Icon  
2/19/2020Sell5,085$2.77$14,085.45236,651View SEC Filing Icon  
1/16/2020Sell11,381$3.37$38,353.97246,678View SEC Filing Icon  
5/14/2019Sell2,388$8.82$21,062.16258,035View SEC Filing Icon  
4/11/2019Sell16,493$10.75$177,299.75260,423View SEC Filing Icon  
4/2/2019Sell1,882$10.57$19,892.74276,988View SEC Filing Icon  
2/20/2019Sell2,285$11.47$26,208.95View SEC Filing Icon  
1/16/2019Sell10,499$10.44$109,609.56231,083View SEC Filing Icon  
6/25/2018Sell235$18.76$4,408.60240,263View SEC Filing Icon  
5/14/2018Sell3,290$18.10$59,549.00View SEC Filing Icon  
4/16/2018Sell3,900$18.60$72,540.00254,694View SEC Filing Icon  
4/2/2018Sell1,948$15.58$30,349.84256,452View SEC Filing Icon  
3/26/2018Sell220$17.41$3,830.20251,476View SEC Filing Icon  
See Full Table

Thomas J. Riga Buying and Selling Activity at Spectrum Pharmaceuticals

This chart shows Thomas J Riga's buying and selling at Spectrum Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Spectrum Pharmaceuticals Company Overview

Spectrum Pharmaceuticals logo
Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development and commercialization of a pipeline of novel and targeted oncology therapies. Its product pipeline includes: Eflapegrastim, Poziotinib, and IGN002. The company was founded in December 1987 and is headquartered in Henderson, NV.
Read More

Today's Range

Now: $0.81
Low: $0.78
High: $0.82

50 Day Range

MA: $0.76
Low: $0.50
High: $1.07

2 Week Range

Now: $0.81
Low: $0.32
High: $1.57


1,121,693 shs

Average Volume

1,873,133 shs

Market Capitalization

$164.86 million

P/E Ratio


Dividend Yield